Ptc Therapeutics, Inc 10-Q for FY2026 Q3
Ptc Therapeutics, Inc. (PTCT)
10-Q
2026-10-29
For: 2026-09-30
View Original
Added on
October 29, 2026
About this 10-Q
Ptc Therapeutics, Inc filed this 10-Q on October 29, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Ptc Therapeutics, Inc. acquired assets primarily related to ST-920 from Sangamo Therapeutics, Inc. in September 2026. Net income was $29.0 million for the nine months ended September 30, 2026, and Sephience generated $181.9 million in net sales during the three months ended September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $357.81M
- up 69.6% from $211.01M a year earlier
- Net loss
- $51.69M
- compared with net income of $15.9M a year earlier
- Diluted EPS
- -$0.62
- compared with $0.20 a year earlier